The analysis indicates that the overall survival rates of AML patients with high and low expression of PIK3CA and AKT1 showed no difference (Fig. 2D and E, Hazard Ratio (HR) = 0.95, p = 0.84 and HR = 0.97, p = 0.91, respectively). This evidence concerns the gene AKT1 and acute myeloid leukemia.